Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from Trevi Therapeutics, Inc.’s reported figures.
Plus components not separately reported this period.
The source filing: Trevi Therapeutics, Inc.’s 10-Q, filed May 5, 2026. Open the filing →
- Filed
- May 5, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-206390
FAQ
- What is Trevi Therapeutics, Inc.'s EBIT?
- Trevi Therapeutics, Inc. (TRVI) reported EBIT of -$14.91M in Q1 2026.
- How has Trevi Therapeutics, Inc.'s EBIT changed year-over-year?
- Trevi Therapeutics, Inc.'s EBIT decreased by 30.0% year-over-year, from -$11.47M to -$14.91M.
- What is the long-term trend for Trevi Therapeutics, Inc.'s EBIT?
- Over 4 years (2021 to 2025), Trevi Therapeutics, Inc.'s EBIT has grown at a 11.0% compound annual growth rate (CAGR), from -$32.48M to -$49.33M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Trevi Therapeutics, Inc.'s ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude